Loading
A phase 1/2 trial of CGT4859 in biliary tract cancer, run by Cogent Biosciences, Inc., active and no longer recruiting.
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06777316 by Cogent Biosciences, Inc., with 110 participants enrolled, started 2025-01-22 and due to reach its primary completion in 2027-03. Interventions recorded: CGT4859.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/